


Certificate of Transmission by Mailing, Facsimile, or Electronic Transmission (37 C.F.R. §1.8)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is:

being deposited with the U.S. Postal Service on the date indicated below and with sufficient postage addressed to Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

being facsimile transmitted to the Commissioner for Patents, U.S.P.T.O. (Fax No. 571-273-8300) on the date indicated below.

being transmitted to the Commissioner for Patents via the U.S.P.T.O. Electronic Filing System on the date indicated below.

 02-Aug-2011
Signature Ann S. Chihak Poff Date of Transmittal

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Johnson, Leisa, et al.	Confirmation No. 5051
Serial No.: 09/714,409	Art Unit: 1632
Filing Date: 14-Nov-2000	Examiner: Nguyen, Dave Trong
Title: AN ONCOLYTIC ADENOVIRUS	

REVOCATION AND SUBSTITUTE POWER OF ATTORNEY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Onyx Pharmaceuticals, Inc., the assignee of the above-identified patent application by virtue of assignments recorded on 26 September 2001 at Reel/Frame 012208/0280, hereby revokes all powers of attorney previously given and hereby appoints the following attorney and agent to prosecute this application and to make alterations and amendments therein. Each of the following attorney and agent has full power of substitution and revocation:

Gregory Giotta (Registration No. 32,028) Gary R. Fabian (Registration No. 33,875)

The undersigned has reviewed all the documents in the chain of title, and to the best of the undersigned's knowledge, title of this application is in the name of Onyx Pharmaceuticals, Inc.

Please direct all future correspondences in connection with this application to:

Customer No. 37499.

No fees are believed due in connection with this paper. However, the Commissioner is hereby authorized to charge to Deposit Account No. 15-0615 (please reference **ONYX 1033.ORD**) any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 which may be required by this paper, with the exception of the payment of the Issue Fee.

Respectfully submitted,

Dated: 8/2/11

By : 

Gregory Giotta, Ph.D., Esq.

Registration No. 32,028

Vice President, Deputy General Counsel

Chief IP Counsel

Onyx Pharmaceuticals, Inc.

ONYX Pharmaceuticals, Inc.
249 E. Grand Ave.
South San Francisco, CA 94080
Phone: (650) 266-2502
Facsimile: (650) 266-0115